Skip to content

   Pharma Publications

Neuropsychopharmacology
  • Is abnormal brain insulin action implicated in the biology of depression? A pilot neuroimaging study in adolescents
    Published on 2026-07-11
    2 weeks ago
  • Neuronal genetic risk within the multicellular landscape of schizophrenia
    Published on 2026-07-10
    3 weeks ago
  • Psychedelics produce enduring enhancement of reward responsiveness in male rats
    Published on 2026-07-10
    3 weeks ago
  • The neuroanatomy of depression: weak but replicable effects in 4021 individuals from three clinical cohorts
    Published on 2026-07-10
    3 weeks ago
  • Does a monoclonal antibody targeting immune cells affect glutamatergic level in schizophrenia? A multimodal PET/MRS brain imaging study
    Published on 2026-07-09
    3 weeks ago
  • Correction: Cue labeling reduces cigarette craving and associated neural activity
    Published on 2026-07-08
    3 weeks ago
  • In memoriam – Ming T. Tsuang, M.D., Ph.D., D.Sc
    Published on 2026-07-08
    3 weeks ago
« Previous 1 2 3 4 5 … 143 Next »
Journal of Psychopharmacology
  • Effects of pimavanserin, xanomeline and highly-purified plant-derived cannabidiol on MK-801-induced behaviours in mice relevant to psychosis
    Published on 2026-06-25
    1 month ago
  • The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential
    Published on 2026-06-25
    1 month ago
  • Pharmacokinetics and pharmacodynamics of orally administered S-ketamine in healthy participants
    Published on 2026-06-25
    1 month ago
  • Angiotensin II and angiotensin-(1–7) neurotransmissions in the medial amygdala differently control cardiovascular and anxiogenic-like responses to stress in rats
    Published on 2026-06-25
    1 month ago
  • A noninvasive approach to modeling cocaine self-administration in mice
    Published on 2026-06-25
    1 month ago
  • Evaluating the abuse liability of ketamine in the treatment of mood disorders: A systematic review
    Published on 2026-06-24
    1 month ago
  • Enhanced cognitive protection through the combination of Amylovis-201, an anti-amyloidogenic agent with sigma-1 receptor agonist activity, and environmental enrichment in mice
    Published on 2026-06-24
    1 month ago
« Previous 1 2 3 4 5 … 150 Next »
European Neuropsychopharmacology
  • Recommendations of the ECNP Digital Network for the evaluation of mental health care apps: A Delphi consensus
    Published on 2026-06-05
    2 months ago
  • Dot the i’s and cross the t’s: Can we get resilience in bipolar disorder right, please?
    Published on 2026-06-03
    2 months ago
  • Reconsidering regression-based predictors in adults with attention‑deficit/hyperactivity disorder and substance use disorders
    Published on 2026-06-02
    2 months ago
  • Prevalence and outcomes of co-occurring psychiatric and endocrine, metabolic, and nutritional disorders: An atlas based on umbrella review of 254,154,533 records
    Published on 2026-05-30
    2 months ago
  • Blinding integrity in psychedelic research: Evidence from a comparative randomized controlled trial of psilocybin, MDMA, and methylphenidate in healthy volunteers
    Published on 2026-05-29
    2 months ago
  • From association to screening: calibrating neurological risk in severe mental illness
    Published on 2026-05-29
    2 months ago
  • Rethinking neurocognitive and cardiometabolic screening in severe mental illness
    Published on 2026-05-23
    2 months ago
« Previous 1 2 3 4 5 … 168 Next »

   Pharma Pub